Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin-1 Levels.

J Sleep ResJun 25, 2026 (epub)
Case ReportNeurology

Ling Shan, Suzan Linssen, Rolf Fronczek et al.

✦ AI-curated · Sources linked

Case in brief

A 42-year-old woman presented with excessive daytime sleepiness since age 15, without cataplexy. Diagnostic tests revealed borderline low-intermediate hypocretin-1 levels and multiple sleep latency tests indicated significant sleepiness. Postmortem analysis showed a marked reduction of CRH neurons in the paraventricular nucleus, similar to findings in narcolepsy type 1. The patient later developed severe depression and committed suicide.

What made this case unusual

The case highlights a significant reduction of CRH neurons in narcolepsy without cataplexy, which is not commonly reported.

Diagnostic / clinical pearl

Clinicians should consider the possibility of CRH neuron loss in patients with narcolepsy without cataplexy, as it may contribute to excessive daytime sleepiness.

Why it matters

Understanding the neurobiological changes in narcolepsy without cataplexy can inform future research and management strategies for this condition.

Source

PubMed · PMID 42348342

Published in J Sleep Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.